Development and application of a Phosphorus Counting Table for control of blood level of phosphorus in patients with Bone Disease in hemodialysis

Not Applicable

• Conditions: Hyperphosphatemia; renal dialysis; chronic Kidney disease-mineral and bone disorder; C18.452.750.199; E02.870.300; C05.116.198.816.750

• Registration Number: RBR-2vzd48
• Lead Sponsor: Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-05-15
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients with chronic kidney disease and disease–mineral and bone disorder in hemodialysis; age range greater than or equal to 18 years; literate or had literate carer; serum phosphorus levels less than or equal to 7,8mg/dL after thirty days of phosphate binder cessation; sign the written informed consent form

Exclusion Criteria

Patients in use of anti-inflammatory hormones; patients with neoplasias or active infectious diseases

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in serum levels of phosphorus based on the observation of a negative variation of 5% in the measurements before and after (30 and 60 days) intervention with the Phosphorus Counting Table;Maintenance in serum levels of phosphorus by observing the measurements before and after (30 and 60 days) intervention with the Phosphorus Counting Table

Secondary Outcome Measures

Name	Time	Method
Reduction in 5% of phosphorus intake by means of analysis of phosphorus intake during before and after intervention through 3-d food record;Maintenance of nutritional status by observing the means of body mass index greater than or equal to 18 Kg/m2 and serum levels of total protein between 6 and 8 g/dL, albumin greater than 3,8 g/dL, total lymphocyte count greater than 1200 mm3, creatinine greater than 9 mg/dL, total cholesterol between 100 and 200 mg/dL and transferrin between 250 and 450 mg/dL during the interval before and after intervention